Research progress of mesenchymal stem cells in the treatment of liver disease

doi:10.16352/j.issn.1001-6325.2023.01.0012

Abstract

Abstract: Liver disease is a serious threat to human health. However, there is still no effective medical treatment for end-stage liver diseases such as cirrhosis and liver failure. Mesenchymal stem cells (MSCs) are expected to be used clinically for liver cirrhosis caused by various etiologies, acute-on-chronic liver failure, chronic liver failure, and complications post-liver transplantation by their multi-directional differentiation and immunomodulatory abilities. MSCs can directly differentiate into hepatocyte-like cells and indirectly secrete soluble factors to achieve goals such as antioxidant, anti-regulated cell death, anti-fibrosis, inhibiting inflammation, inhibiting immune response, etc., so to reduce liver damage and improve survival rate. A sound quality standard evaluation system and a more in-depth mechanism exploration are the prerequisites for MSCs to be used in the clinical treatment of liver diseases in the future.

Key words: liver disease, mesenchymal stem cells, clinical treatment, mechanism

CLC Number:

R575.3

ZHOU Jiahang, CHEN Junyao, CAO Hongcui. Research progress of mesenchymal stem cells in the treatment of liver disease[J]. Basic & Clinical Medicine, 2023, 43(1): 12-20.

References 58

[1]	Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease[J]. Nat Rev Immunol, 2008, 8: 726-736.
[2]	Lazarus HM, Haynesworth SE, Gerson SL, et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use.[J]. Bone Marrow Transplant, 1995, 16: 557-564.
[3]	Arroyo V, Moreau R, Kamath PS, et al. Acute-on-chronic liver failure in cirrhosis[J]. Nat Rev Dis Prim, 2016, 2: 1-18.
[4]	Shi M, Zhang Z, Xu R, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients[J]. Stem Cells Transl Med, 2012, 1: 725-731.
[5]	Lin BL, Chen JF, Qiu WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial[J]. Hepatology, 2017, 66: 209-219.
[6]	中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018 年版)[J]. 临床肝胆病杂志, 2019, 35: 38-44.
[7]	Peng L, Xie DY, Lin BL, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes[J]. Hepatology, 2011, 54: 820-828.
[8]	Xu L, Gong Y, Wang B, et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells[J]. J Gastroenterol Hepatol, 2014, 29: 1620-1628.
[9]	Mohamadnejad M, Alimoghaddam K, Bagheri M, et al. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis[J]. Liver Int, 2013, 33: 1490-1496.
[10]	Zhang Z, Lin H, Shi M, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients[J]. J Gastroenterol Hepatol, 2012, 27: 112-120.
[11]	Fang X, Liu L, Dong J, et al. A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B-induced decompensated liver cirrhosis[J]. J Gastroenterol Hepatol, 2018, 33: 774-780.
[12]	Shi M, Li YY, Xu RN, et al. Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial[J]. Hepatol Int, 2021, 15: 1431-1441.
[13]	Amer MEM, El-Sayed SZ, El-Kheir WA, et al. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells[J]. Eur J Gastroenterol Hepatol, 2011, 23: 936-941.
[14]	Amin MA, Sabry D, Rashed LA, et al. Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: Egyptian study[J]. Clin Transplant, 2013, 27: 607-612.
[15]	El-Ansary M, Abdel-Aziz I, Mogawer S, et al. Phase II trial: undifferentiated versus differentiated autologous mesen-chymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis[J]. Stem Cell Rev Reports, 2012, 8: 972-981.
[16]	Salama H, Zekri ARN, Medhat E, et al. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease[J]. Stem Cell Res Ther, 2014, 5: 70.
[17]	Jang YO, Kim YJ, Baik SK, et al. Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study[J]. Liver Int, 2014, 34: 33-41.
[18]	Saadatmand S, Vos JR, Hooning MJ, et al. Transplanta-tion with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial[J]. Hepatology, 2016, 64: 2185-2197.
[19]	Wang L, Han Q, Chen H, et al. Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis[J]. Stem Cells Dev, 2014, 23: 2482-2489.
[20]	Wang L, Li J, Liu H, et al. A pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis[J]. J Gastroenterol Hepatol, 2013, 28: 85-92.
[21]	Liang J, Zhang H, Zhao C, et al. Effects of allogeneic mesenchymal stem cell transplantation in the treatment of liver cirrhosis caused by autoimmune diseases[J]. Int J Rheum Dis, 2017, 20: 1219-1226.
[22]	Schacher FC, Martins Pezzi Da Silva A, Silla LMDR, et al. Bone marrow mesenchymal stem cells in acute-on-chronic liver failure grades 2 and 3: a phase I-II randomized clinical trial[J]. Can J Gastroenterol Hepatol, 2021, 2021: 3662776.
[23]	Kantarciogğlu M, Demirci H, Avcu F, et al. Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis[J]. Turkish J Gastroenterol, 2015, 26: 244-250.
[24]	Kharaziha P, Hellström PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial[J]. Eur J Gastroenterol Hepatol, 2009, 21: 1199-1205.
[25]	Sakai Y, Takamura M, Seki A, et al. Phase I clinical study of liver regenerative therapy for cirrhosis by intrahepatic arterial infusion of freshly isolated autologous adipose tissue-derived stromal/stem (regenerative) cell[J]. Regen Ther, 2017, 6: 52-64.
[26]	Zhang YC, Liu W, Fu BS, et al. Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation[J]. Cytotherapy, 2017, 19: 194-199.
[27]	Zhang Y, Zhang J, Yi H, et al. A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial[J]. Stem Cell Res Ther, 2021, 12: 1-15.
[28]	Shi M, Liu Z, Wang Y, et al. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection[J]. Stem Cells Transl Med, 2017, 6: 2053-2061.
[29]	Casiraghi F, Perico N, Podestà MA, et al. Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: a randomized controlled trial[J]. Am J Transplant, 2021, 21: 2795-2809.
[30]	Detry O, Vandermeulen M, Delbouille MH, et al. Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase I-II, open-label, clinical study[J]. J Hepatol, 2017, 67: 47-55.
[31]	Alizadeh E, Eslaminejad MRB, Akbarzadeh A, et al. Upregulation of miR-122 via trichostatin A treatments in hepatocyte-like cells derived from mesenchymal stem cells[J]. Chem Biol Drug Des, 2016, 87: 296-305.
[32]	Xu F, Liu J, Deng J, et al. Rapid and high-efficiency generation of mature functional hepatocyte-like cells from adipose-derived stem cells by a three-step protocol[J]. Stem Cell Res Ther, 2015, 6: 1-10.
[33]	Zhao Q, Ren H, Li X, et al. Differentiation of human umbilical cord mesenchymal stromal cells into low immunogenic hepatocyte-like cells[J]. Cytotherapy, 2009, 11: 414-426.
[34]	An SY, Han J, Lim HJ, et al. Valproic acid promotes differentiation of hepatocyte-like cells from whole human umbilical cord-derived mesenchymal stem cells[J]. Tissue Cell, 2014, 46: 127-135.
[35]	Li H, Zhu L, Chen H, et al. Generation of functional hepatocytes from human adipose-derived MYC+ KLF4+ GMNN+ stem cells analyzed by single-cell RNA-seq profiling[J]. Stem Cells Transl Med, 2018, 7: 792-805.
[36]	Li J, Yang Y, Fan J, et al. Long noncoding RNA ANCR inhibits the differentiation of mesenchymal stem cells toward definitive endoderm by facilitating the association of PTBP1 with ID2[J]. Cell Death Dis, 2019, 10: 492.
[37]	Sato Y, Araki H, Kato J, et al. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion[J]. Blood, 2005, 106: 756-763.
[38]	Cao H, Yang J, Yu J, et al. Therapeutic potential of transplanted placental mesenchymal stem cells in treating Chinese miniature pigs with acute liver failure[J]. BMC Med, 2012, 10: 56.
[39]	Aurich H, Sgodda M, Kaltwasser P, et al. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo[J]. Gut, 2009, 58: 570-581.
[40]	Campard D, Lysy PA, Najimi M, et al. Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells[J]. Gastroenterology, 2008, 134: 833-848.
[41]	Gentile P, Garcovich S, Bielli A. Human menstrual blood-derived stem cells ameliorate liver fibrosis in mice by targeting hepatic stellate cells via paracrine mediators[J]. Stem Cells Transl Med, 2017, 6: 272-284.
[42]	Quintanilha LF, Takami T, Hirose Y, et al. Canine mesenchymal stem cells show antioxidant properties against thioacetamide-induced liver injury in vitro and in vivo[J]. Hepatol Res, 2014, 44: E206-E217.
[43]	Cho K, Woo S, Seoh J, et al. Mesenchymal stem cells restore CCl4-induced liver injury by an antioxidative process[J]. Cell Biol Int, 2012, 36: 1267-1274.
[44]	Tang D, Kang R, Berghe TV, et al. The molecular machinery of regulated cell death[J]. Cell Res, 2019, 29: 347-364.
[45]	Van Poll D, Parekkadan B, Cho CH, et al. Mesenchymal stem cell-derived molecules directly modulate hepato-cellular death and regeneration in vitro and in vivo[J]. Hepatology, 2008, 47: 1634-1643.
[46]	Lin F, Chen W, Zhou J, et al. Mesenchymal stem cells protect against ferroptosis via exosome-mediated stabiliza-tion of SLC7A11 in acute liver injury[J]. Cell Death Dis, 2022, 13: 271.
[47]	An SY, Jang YJ, Lim HJ, et al. Milk fat globule-EGF factor 8, secreted by mesenchymal stem cells, protects against liver fibrosis in mice[J]. Gastroenterology, 2017, 152: 1174-1186.
[48]	Wang S, Kim J, Lee C, et al. Tumor necrosis factor-inducible gene 6 reprograms hepatic stellate cells into stem-like cells, which ameliorates liver damage in mouse[J]. Biomaterials, 2019, 219: 119375.
[49]	Wang M, Zhang M, Fu L, et al. Liver-targeted delivery of TSG-6 by calcium phosphate nanoparticles for the management of liver fibrosis[J]. Theranostics, 2020, 10: 36-49.
[50]	Milosavljevic N, Gazdic M, Simovic Markovic B, et al. Mesenchymal stem cells attenuate liver fibrosis by suppressing Th17 cells-an experimental study[J]. Transpl Int, 2018, 31: 102-115.
[51]	Lee KC, Lin HC, Huang YH, et al. Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease[J]. J Hepatol, 2015, 63: 1405-1412.
[52]	Li C, Jin Y, Wei S, et al. Hippo signaling controls NLR family pyrin domain containing 3 activation and governs immunoregulation of mesenchymal stem cells in mouse liver injury[J]. Hepatology, 2019, 70: 1714-1731.
[53]	Wang J, Liu Y, Ding H, et al. Mesenchymal stem cell-secreted prostaglandin E2 ameliorates acute liver failure via attenuation of cell death and regulation of macrophage polarization[J]. Stem Cell Res Ther, 2021, 12: 1-13.
[54]	Zhou J, Feng X, Zhu J, et al. Mesenchymal stem cell treatment restores liver macrophages homeostasis to alleviate mouse acute liver injury revealed by single-cell analysis[J]. Pharmacol Res, 2022, 179: 106229.
[55]	Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation[J]. Blood, 2004, 103: 4619-4621.
[56]	Plumas J, Chaperot L, Richard MJ, et al. Mesenchymal stem cells induce apoptosis of activated T cells[J]. Leukemia, 2005, 19: 1597-1604.
[57]	Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells[J]. Blood, 2007, 109: 228-234.
[58]	Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide[J]. Cell Stem Cell, 2008, 2: 141-150.